发明名称 |
INTRALYMPHATIC CHEMOTHERAPY DRUG CARRIERS |
摘要 |
<p>A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 50 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer.</p> |
申请公布号 |
EP2242514(B1) |
申请公布日期 |
2015.09.30 |
申请号 |
EP20090704979 |
申请日期 |
2009.01.30 |
申请人 |
UNIVERSITY OF KANSAS |
发明人 |
FORREST, LAIRD;COHEN, MARK;CAI, SHUANG |
分类号 |
A61K47/48;A61K9/08;A61K33/24;A61K47/30;A61P35/00 |
主分类号 |
A61K47/48 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|